SIC
ALXN

Salem Investment Counselors’s Alexion Pharmaceuticals ALXN Stock Holding History

Salem Investment Counselors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,075
Closed -$168K – 949
2020
Q4 		$168K Hold
1,075
– – 0.01% 292
2020
Q3 		$123K Hold
1,075
– – 0.01% 285
2020
Q2 		$121K Buy
1,075
+1,050
+4,200% +$111K 0.01% 282
2020
Q1 		$2K Sell
25
-165
-87% -$16.2K ﹤0.01% 638
2019
Q4 		$21K Sell
190
-36,950
-99% -$3.95M ﹤0.01% 487
2019
Q3 		$3.64M Sell
37,140
-810
-2% -$91.3K 0.33% 69
2019
Q2 		$4.97M Buy
37,950
+1,305
+4% +$168K 0.46% 55
2019
Q1 		$5.09M Sell
36,645
-2,345
-6% -$292K 0.52% 49
2018
Q4 		$3.8M Buy
38,990
+2,345
+6% +$277K 0.48% 51
2018
Q3 		$5.09M Buy
36,645
+3,835
+12% +$481K 0.52% 49
2018
Q2 		$4.07M Buy
32,810
+905
+3% +$106K 0.37% 57
2018
Q1 		$3.45M Buy
31,905
+31,825
+39,781% +$3.8M 0.39% 65
2017
Q4 		$10K Sell
80
-131
-62% -$16K ﹤0.01% 460
2017
Q3 		$30K Hold
211
– – ﹤0.01% 360
2017
Q2 		$26K Buy
+211
New +$24.6K ﹤0.01% 381

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Salem Investment Counselors's ALXN Position: Q1 2021 in Review

Salem Investment Counselors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,075 shares — an estimated $168K sold.

Salem Investment Counselors first reported a position in ALXN in Q2 2017 and held it in 15 quarters. The position peaked at $5.09M in Q1 2019. 753 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Salem Investment Counselors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Salem Investment Counselors sold 1,075 Alexion Pharmaceuticals shares in Q1 2021, an estimated $168K.
  • Salem Investment Counselors first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 15 quarters.
  • Salem Investment Counselors's Alexion Pharmaceuticals position peaked at $5.09M in Q1 2019.
  • 753 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Salem Investment Counselors's 13F filing for Q1 2021, filed 17 May 2021.